DNA Capital VC II LP

The absence of prior EDGAR filings from DNA Capital indicates this is either a first institutional fund from the management team or a rebranding of an earlier vehicle, meaning LPs cannot benchmark this GP's follow-on discipline, J-curve management, or exit execution against a prior vintage—making operational references and LP calls on Fund I critical diligence steps.

A May 2026 filing for a $100M Brazil-focused VC fund aligns with renewed institutional appetite for emerging-market tech allocations as LP diversification outside US/Europe increases, though the 4% close at filing suggests either a very early-stage raise or significant difficulty in landing anchor commitments despite pre-existing relationship exemption.

Verify whether Fund I exists and its final close date, capital deployed, and exit timeline—if this is truly a first fund masquerading as a sequel, or if Fund I is still actively deploying capital, the overlap creates both GP distraction risk and potential LP conflict-of-interest issues that should be explicitly addressed in fund governance documents.